PPAR Is Required for PPAR δ Action in Regulation of Body Weight and Hepatic Steatosis in Mice

PPAR Research

Volumn 2015, Issue , 2015, Pages

  Garbacz, Wojciech G ^a   Huang, Jeffrey T J ^a   Higgins, Larry G ^a   Wahli, Walter ^b,c,d   Palmer, Colin N A ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^d TOXALIM RESEARCH CENTRE IN FOOD TOXICOLOGY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DNA BINDING; FATTY LIVER; GENE DELETION; LIPID LIVER LEVEL; LIPID STORAGE; MOUSE; NONHUMAN; PHYSIOLOGICAL PROCESS; WEIGHT REDUCTION; WILD TYPE;

EID: 84947254537     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2015/927057     Document Type: Article

References (61)

1. R. Stienstra, C. Duval, M. Müller, and S. Kersten, "PPARs, obesity, and inflammation," PPAR Research, vol. 2007,Article ID 95974, 10 pages, 2007.
2. G. D. Barish, V. A. Narkar, and R.M. Evans, "PPAR: a dagger in the heart of the metabolic syndrome,"The Journal of Clinical Investigation, vol. 116, no. 3, pp. 590-597, 2006.
3. T. Varga, Z. Czimmerer, and L.Nagy, "PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation," Biochimica et Biophysica Acta, vol. 1812, no. 8, pp. 1007-1022, 2011.
4. C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli, "Control of the peroxisomal oxidation pathway by a novel family of nuclear hormone receptors," Cell, vol. 68, no. 5, pp. 879-887, 1992.
5. C. N. A. Palmer, M.-H. Hsu, K. J. Griffin, and E. F. Johnson, "Novel sequence determinants in peroxisome proliferator signaling," The Journal of Biological Chemistry, vol. 270, no. 27, pp. 16114-16121, 1995.
6. U. Seedorf and J. Aberle, "Emerging roles of PPAR in metabolism," Biochimica et Biophysica Acta, vol. 1771, no. 9, pp. 1125-1131, 2007.
7. I. Issemann and S.Green, "Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators," Nature, vol. 347, no. 6294, pp. 645-650, 1990.
8. S. S.-T. Lee, T. Pineau, J. Drago et al., "Targeted disruption of the isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators," Molecular and Cellular Biology, vol. 15, no. 6, pp. 3012-3022, 1995.
9. C. N. A. Palmer, M.-H. Hsu, K. J. Griffin, J. L. Raucy, and E. F. Johnson, "Peroxisome proliferator activated receptor-alpha expression in human liver,"Molecular Pharmacology, vol. 53,no. 1, pp. 14-22, 1998.
10. C. Christodoulides and A. Vidal-Puig, "PPARs and adipocyte function," Molecular and Cellular Endocrinology, vol. 318, no. 1-2, pp. 61-68, 2010.
11. F. Karpe and E. E. Ehrenborg, "PPAR in humans: genetic and pharmacological evidence for a significantmetabolic function," Current Opinion in Lipidology, vol. 20, no. 4, pp. 333-336, 2009.
12. U. Ris̈erus, D. Sprecher, T. Johnson et al., "Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men," Diabetes, vol. 57, no. 2, pp. 332-339, 2008.
13. T. L. Graham, C. Mookherjee, K. E. Suckling, C. N. A. Palmer, and L. Patel, "ThePPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice," Atherosclerosis, vol. 181, no. 1, pp. 29-37, 2005.
14. G.D. Barish, A. R. Atkins,M.Downes et al., "PPAR regulates multiple proinflammatory pathways to suppress atherosclerosis," Proceedings of theNationalAcademy of Sciences of theUnited States of America, vol. 105, no. 11, pp. 4271-4276, 2008.
15. J. Youssef and M. Badr, "Peroxisome proliferator-activated receptors and cancer: challenges and opportunities," British Journal of Pharmacology, vol. 164, no. 1, pp. 68-82, 2011.
16. C.-H. Lee, P. Olson, A. Hevener et al., "PPAR regulates glucose metabolism and insulin sensitivity," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 9, pp. 3444-3449, 2006.
17. S. Liu, B. Hatano, M. Zhao et al., "Role of peroxisome proliferator-activated receptor/in hepatic metabolic regulation," The Journal of Biological Chemistry, vol. 286, no.2,pp. 1237-1247, 2011.
18. X. Qin, X. Xie, Y. Fan et al., "Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice," Hepatology, vol. 48, no. 2, pp. 432-441, 2008.
19. L. Michalik, B. Desvergne, N. S. Tan et al., "Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR) and PPAR mutant mice," Journal of Cell Biology, vol. 154, no. 4, pp. 799-814, 2001.
20. M.Romanowska, L. Reilly,C.N.A.Palmer,M. C.U.Gustafsson, and J. Foerster, "Activation of PPARbeta/delta causes a psoriasislike skin disease in vivo," PLoS ONE, vol. 5, no. 3, Article ID e9701, 2010.
21. L. G. Higgins, W. G. Garbacz, M. C. Gustafsson et al., "Conditional expression of human PPAR and a dominant negative variant of hPPAR in vivo," PPAR Research, vol. 2012,Article ID 216817, 12 pages, 2012.
22. S. J.Campbell, F. Carlotti, P.A.Hall, A. J. Clark, andC. R.Wolf, "Regulation of the CYP1A1 promoter in transgenic mice: an exquisitely sensitive on-off system for cell specific gene regulation," Journal of Cell Science, vol. 109, part 11, pp. 2619-2625, 1996.
23. J. Folch, M. Lees, and G. H. Sloane Stanley, "A simple method for the isolation and purification of total lipides from animal tissues,"The Journal of Biological Chemistry, vol. 226, no. 1, pp. 497-509, 1957.
24. E. J. C. G. van denOord, "Controlling false discoveries in genetic studies," American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics, vol. 147, no. 5, pp. 637-644, 2008.
25. U. Sommer, H. Herscovitz, F.K.Welty, and C. E. Costello, "LCMS-based method for the qualitative and quantitative analysis of complex lipidmixtures," Journal of Lipid Research, vol. 47, no. 4, pp. 804-814, 2006.
26. T. V. Beischlag, J. L. Morales, B. D. Hollingshead, and G. H. Perdew, "The aryl hydrocarbon receptor complex and the control of gene expression," Critical Reviews in Eukaryotic Gene Expression, vol. 18, no. 3, pp. 207-250, 2008.
27. U. Edvardsson, A. Ljungberg, D. Linden et al., "PPAR activation increases triglyceride mass and adipose differentiationrelated protein in hepatocytes," Journal of Lipid Research, vol. 47, no. 2, pp. 329-340, 2006.
28. T. C. Leone, C. J. Weinheimer, and D. P. Kelly, "A critical role for the peroxisome proliferator-activated receptor (PPAR) in the cellular fasting response: the PPAR-null mouse as a model of fatty acid oxidation disorders," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 13, pp. 7473-7478, 1999.
29. S. Kersten, J. Seydoux, J. M. Peters, F. J. Gonzalez, B. Desvergne, and W. Wahli, "Peroxisome proliferator-activated receptor mediates the adaptive response to fasting," The Journal of Clinical Investigation, vol. 103, no. 11, pp. 1489-1498, 1999.
30. M. Araki and K.Motojima, "Identification of ERR as a specific partner of PGC-1 for the activation of PDK4 gene expression in muscle," FEBS Journal, vol. 273, no. 8, pp. 1669-1680, 2006.
31. M. V. Chakravarthy, I. J. Lodhi, L. Yin et al., "Identification of a physiologically relevant endogenous ligand for PPAR in liver," Cell, vol. 138, no. 3, pp. 476-488, 2009.
32. E. Barroso, R. Rodŕ?guez-Calvo, L. Serrano-Marco et al., "The PPAR/ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1-lipin 1-PPAR pathway leading to increased fatty acid oxidation," Endocrinology, vol. 152, no. 5, pp. 1848-1859, 2011.
33. R. N. Hardwick, C. D. Fisher, M. J. Canet, G. L. Scheffer, and N. J. Cherrington, "Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease," Drug Metabolism and Disposition, vol. 39, no. 12, pp. 2395-2402, 2011.
34. V. R. More, X. Wen, P. E. Thomas, L. M. Aleksunes, and A. L. Slitt, "Severe diabetes and leptin resistance cause differential hepatic and renal transporter expression in mice," Comparative Hepatology, vol. 11, article 1, 2012.
35. M. C. F. J. de Rotte, M. Bulatovic, M.W. Heijstek et al., "ABCB1 and ABCC3 gene polymorphisms are associated with firstyear response to methotrexate in juvenile idiopathic arthritis," Journal of Rheumatology, vol. 39, no. 10, pp. 2032-2040, 2012.
36. P. Huypens, R. Pillai, T. Sheinin et al., "The dicarboxylate carrier plays a role in mitochondrialmalate transport and in the regulation of glucose-stimulated insulin secretion from rat pancreatic beta cells," Diabetologia, vol. 54, no. 1, pp. 135-145, 2011.
37. N. Guilĺen, M. A. Navarro, C. Arnal et al., "Microarray analysis of hepatic gene expression identifies new genes involved in steatotic liver," Physiological Genomics, vol. 37,no. 3, pp. 187-198, 2009.
38. H. Völzke, M. Nauck, R. Rettig et al., "Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample," European Journal of Endocrinology, vol. 161, no. 5, pp. 705-713, 2009.
39. V. A. Narkar, M. Downes, R. T. Yu et al., "AMPK and PPAR agonists are exercise mimetics," Cell, vol. 134, no. 3, pp. 405-415, 2008.
40. E. E. Girroir, H. E. Hollingshead, P. He, B. Zhu, G. H. Perdew, and J. M. Peters, "Quantitative expression patterns of peroxisome proliferator-activated receptor-/ (PPAR/) protein in mice," Biochemical and Biophysical Research Communications, vol. 371, no. 3, pp. 456-461, 2008.
41. T. Adhikary, K. Kaddatz, F. Finkernagel et al., "Genomewide analyses define different modes of transcriptional regulation by peroxisome proliferator-activated receptor-beta/delta (PPARbeta/ delta)," PLoS ONE, vol. 6, no. 1, Article ID e16344, 2011.
42. M. C. U. Gustafsson, D. Knight, and C. N. A. Palmer, "Ligand modulated antagonismof PPAR by genomic and non-genomic actions of PPAR," PLoS ONE, vol. 4, no. 9, Article ID e7046, 2009.
43. P. Tessari, A. Coracina, A. Cosma, and A. Tiengo, "Hepatic lipid metabolism and non-alcoholic fatty liver disease," Nutrition, Metabolism and Cardiovascular Diseases, vol. 19, no. 4, pp. 291-302, 2009.
44. P. Nguyen, V. Leray, M. Diez et al., "Liver lipid metabolism," Journal of Animal Physiology and Animal Nutrition, vol. 92, no. 3, pp. 272-283, 2008.
45. Y. Jia, J.-Y. Kim, H.-J. Jun et al., "Thenatural carotenoid astaxanthin, a PPAR- agonist and PPAR- antagonist, reduces hepatic lipid accumulation by rewiring the transcriptome in lipidloaded hepatocytes," Molecular Nutrition and Food Research, vol. 56, no. 6, pp. 878-888, 2012.
46. Y. Wei, R. S. Rector, J. P. Thyfault, and J. A. Ibdah, "Nonalcoholic fatty liver disease and mitochondrial dysfunction," World Journal of Gastroenterology, vol. 14, no. 2, pp. 193-199, 2008.
47. T. Tanaka, J. Yamamoto, S. Iwasaki et al., "Activation of peroxisome proliferator-activated receptor induces fatty acid -oxidation in skeletal muscle and attenuates metabolic syndrome," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15924-15929, 2003.
48. A.-M.Mustonen, R. Kakela, T.Halonen, V. Karja, E. Vartiainen, and P. Nieminen, "Fatty acid mobilization in voles-model species for rapid fasting response and fatty liver," Comparative Biochemistry and Physiology-AMolecular and Integrative Physiology, vol. 163, no. 1, pp. 152-160, 2012.
49. E. P. Mottillo, A. E. Bloch, T. Leffs, and J. G. Granneman, "Lipolytic products activate peroxisome proliferator-activated receptor (PPAR)alpha and delta in brown adipocytes to match fatty oxidation with supply," Journal of Biological Chemistry, vol. 287, no. 30, pp. 25038-25048, 2012.
50. V. van Ginneken, E. Verhey, R. Poelmann et al., "Metabolomics (liver and blood profiling) in a mouse model in response to fasting: a study of hepatic steatosis," Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, vol. 1771, no. 10, pp. 1263-1270, 2007.
51. R. K. Berge, K. J. Tronstad, K. Berge et al., "The metabolic syndrome and the hepatic fatty acid drainage hypothesis," Biochimie, vol. 87, no. 1, pp. 15-20, 2005.
52. L. Moller, H. Stodkilde-Jorgensen, F. T. Jensen, and J. O. L. Jorgensen, "Fasting in healthy subjects is associated with intrahepatic accumulation of lipids as assessed by 1H-magnetic resonance spectroscopy," Clinical Science, vol. 114, no. 7-8, pp. 547-552, 2008.
53. A. C. Heijboer, E. Donga, P. J. Voshol et al., "Sixteen hours of fasting differentially affects hepatic andmuscle insulin sensitivity in mice," Journal of Lipid Research, vol. 46, no. 3, pp. 582-588, 2005.
54. S. A. Harrison and C. P. Day, "Recent advances in clinical practice: benefits of lifestyle modification in NAFLD," Gut, vol. 56, no. 12, pp. 1760-1769, 2007.
55. C. Hu, M. Hoene, X. Zhao et al., "Lipidomics analysis reveals efficient storage of hepatic triacylglycerides enriched in unsaturated fatty acids after one bout of exercise in mice," PLoS ONE, vol. 5, no. 10, Article ID e13318, 2010.
56. M. Perreault, S. Will, D. Panza et al., "Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice," Diabetes, Obesity and Metabolism, vol. 12, no. 3, pp. 234-245, 2010.
57. W. R. Oliver Jr., J. L. Shenk, M. R. Snaith et al., "A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport," Proceedings of the National Academy of Sciences of the United States of America , vol. 98, no. 9, pp. 5306-5311, 2001.
58. M. Terada, M. Araki, B. Ashibe, and K. Motojima, "GW501516 acts as an efficient PPAR activator in the mouse liver," Drug Discoveries & Therapeutics, vol. 5, no. 4, pp. 176-180, 2011.
59. S. Yu,K.Matsusue, P.Kashireddy et al., "Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor 1 (PPAR1) overexpression," The Journal of Biological Chemistry, vol. 278, no. 1, pp. 498-505, 2003.
60. H. Staiger, C.Haas, J.Machann et al., "Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome proliferator-activated receptor (PPAR)- and is of metabolic relevance in humans," Diabetes, vol. 58,no. 3, pp. 579-589, 2009.
61. N. E.Gray, L. N. Lam, K. Yang,A.Y.Zhou, S. Koliwad, and J.-C. Wang, "Angiopoietin-like 4 (Angptl4) protein is a physiological mediator of intracellular lipolysis in murine adipocytes," The Journal of Biological Chemistry, vol. 287, no. 11, pp. 8444-8456, 2012.